NCT01183117已完成3 期
A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease
Johnson & Johnson K.K. Medical Company1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2010年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Non-TVF(Target-vessel failure) rate
研究概览
简要总结
The main objective is to evaluate the safety and efficacy of SM-01 stenting (Cordis S.M.A.R.T.™ Nitinol Stent System) for the treatment of SFA lesions as compared to PTA (balloon angioplasty). If SM-01 is used in a PTA-bailout patient, the case will be assessed separately.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 20 years.
- •Symptomatic leg ischemia by Rutherford Classification (category1, 2, or 3).
- •Lesion length >= 40 mm to <= 150 mm. (must be treatable with no more than two SM-01 stents. Overlap should be about 1cm if two stents are used)
- •Reference vessel diameter (RVD) >= 4.0 mm and <= 7.0 mm.
- •All lesions are to be located >= 3.0 cm proximal to the superior edge of the patella, and >= 1.0 cm distal to the SFA / PFA bifurcation.
- •>= 50% stenosis or total occlusion.
- •Patent infrapopliteal and popliteal arteries, i.e., single-vessel runoff or better with at least one of three vessels patent (< 50% stenosis) to the ankle or foot.
- •Patient or legally authorized representative must provide written informed consent prior to initiation of study procedures.
- •A patient with bilateral obstructive SFA disease is eligible for enrollment into the study. If a patient with bilateral disease is enrolled, the target limb will be the more severe limb. The more severe limb will be selected according to clinical symptomatology. If clinical symptomatology is similar, the more clinically severe lesion will be selected. The contralateral procedure should not be done until at least 30 days after the index procedure of the more severe limb was attempted.
排除标准
- •Recent hemorrhagic disease within the past 3 months.
- •Aneurysm in the SFA or popliteal artery.
- •Acute limb occlusion.
- •Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as severe calcification which is resistant to stenting, or for in-stent restenosis.
- •Poor iliac or common femoral "inflow".(However, intervention to restore adequate blood flow prior to the treatment of the study lesion is allowed.)
- •Known allergies to aspirin, heparin, or ticlopidine, or bleeding diathesis.
- •Patients unable or unwilling to tolerate anticoagulant or antiplatelet therapy.
- •Patients unable or unwilling to tolerate contrast agents used in intravascular procedures.
- •Allergic to nitinol or tantalum.
- •Women who are pregnant or lactating, or of child bearing potential, or with a desire to be a parent during the study period.
- •Significant vessel tortuosity or other parameters prohibiting access to the lesion or which would prevent delivery of the stent device.
- •Revascularization involving the same limb 30 days prior to the index procedure or a planned re-vascularization within 30 days after the index procedure.
- •Previously implanted stent(s) at the same site in the artery to be treated.
- •Requiring stent placement in the distal SFA or popliteal artery.
- •Presence of a femoral artificial graft.
- •History of participating in any other clinical study within 1 year.
- •Life expectancy less than 3 years, or any other factors preventing clinical follow-up.
- •Receiving dialysis or immunosuppressant therapy
- •Serum creatinine level >= 2.0 mg/dL before procedure.
- •A principal investigator or a co-principal investigator determines that patient is unsuitable for this study.
结局指标
主要结局
Non-TVF(Target-vessel failure) rate
时间窗: 12 Months
The primary endpoint will be freedom from TVF defined as any events of clinical driven (confirmed by duplex ultrasound or angiography) TLR/TVR, procedure failure, amputation of the target lesion's leg, procedure or device related death, occlusion of target lesion, or \> 70% restenosis of target lesion.
次要结局
- Stent Fracture rate(12 Months)
- Major Clinical Event rate(12 Months)
- Procedure Success rate(12 Months)
- Non-TLR/TVR rate(12 Months)
- Difference between pre and post procedure of QOL (SF-36)(12 Months)
- Difference between pre and post procedure of Rutherford Categories(12 Months)
- Procedure Success rate for Bailout(12 Months)
- Difference between pre and post proceduer of ABI(12 Months)
- Primary Patency rate(12 Months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A clinical investigation of SM-01 stenting versus balloon angioplasty for the treatment of superficial femoral artery disease.Patient with intermittent claudication who shows no sign of improvement with exercise or drug treatment. The SFA lesion(s) should be de novo or restenotic (one long or multiple, serial native lesions with total length >= 40 mm and <= 150 mm).JPRN-UMIN000003928Johnson and Johnson K.K. Medical Company100
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701
已完成
不适用
A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese PatientsArterial Occlusive DiseaseNCT01746550C. R. Bard70
已完成
4 期
The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ StentArterial Occlusive DiseasesNCT00235131Cordis Corporation200
招募中
不适用
Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic PancreatitisBenign Biliary StrictureChronic PancreatitisNCT06655051Changhai Hospital134